Aurobindo Pharma Limited — Important, 05-03-2025: General Updates

Auro Vaccines Private Limited, a wholly owned step-down subsidiary of Aurobindo Pharma, has terminated its License Agreement with Hilleman Laboratories Singapore Pte, Limited. This agreement, established to develop and commercialize a pentavalent vaccine candidate for children's vaccination, was in effect for a brief period. Importantly, Auro Vaccines is not considered a material subsidiary, and this termination is not expected to materially impact the company's overall operations or financials. The company remains committed to keeping shareholders updated on any future developments that may significantly affect its performance.